Skip to search formSkip to main contentSkip to account menu

umeclidinium / vilanterol

Known as: UMECLIDINIUM/VILANTEROL 
National Institutes of Health

Related topics

Related topics

3 relations
7 ACTUAT umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhalerumeclidiniumvilanterol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
The effect of delaying initiation with umeclidinium/vilanterol in patients with COPD: an observational administrative claims database analysis using marginal structural models
BackgroundChronic obstructive pulmonary disease (COPD) is associated with high clinical and economic burden. Optimal… 
Review
2015
Review
2015
Umeclidinium bromide/vilanterol combination in the treatment of chronic obstructive pulmonary disease: a review
Chronic obstructive pulmonary disease (COPD) is a common disease among the elderly that could be prevented by smoking cessation… 
Review
2014
Review
2014
Comparative assessment of umeclidinium/vilanterol (UMEC/VI) combination therapy among symptomatic COPD patients
UMEC/VI is a novel LAMA and LABA combination therapy in a single inhaler. This study assessed comparative efficacy of UMEC/VI(62… 
2013
2013
Long-term safety and tolerability of umeclidinium/vilanterol and umeclidinium in COPD
Background: The long-acting muscarinic antagonist umeclidinium (UMEC) is in development as monotherapy and in combination with… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)